Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data

Bibliography

• Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61(4):1-117
   PubMedGoogle Scholar
• Jernberg T, Johanson P, Held C, SWEDEHEART/RIKS-HIA. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011;305(16):1677-84
   PubMed Web of Science ®Google Scholar
• Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: new pharmacological agents and changing paradigms. J Thromb Haemost 2013;11(Suppl 1):316-29
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502; Erratum in: N Engl J Med 2001;345(20):1506. N Engl J Med 2001;345(23):1716
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Becker RC, Budaj A, PLATO Investigatorset al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Collet JP, Montalescot G. P2Y12 inhibitors: thienopyridines and direct oral inhibitors. Hamostaseologie 2009;29(4):339-48
   PubMed Web of Science ®Google Scholar
• Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30(16):1964-77
   PubMed Web of Science ®Google Scholar
• Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13(7):407-13
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120(25):2577-85
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116(25):2923-32
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50(19):1852-6
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56(18):1456-62
   PubMed Web of Science ®Google Scholar
• Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011;105(Suppl 1):S75-81
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50(19):1844-51; Erratum in: J Am Coll Cardiol. 2007;50(22):2196
   PubMed Web of Science ®Google Scholar
• Sherwood MW, Wiviott SD, Peng SA, et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc 2014;3(2):e000849
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SCJr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54(23):2205-41
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):529-55
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. 2011 WRITING GROUP MEMBERS; ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123(18):e426-579
   PubMed Web of Science ®Google Scholar
• Wijns W, Kolh P, Danchin N, et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization. Eur Heart J 2010;31(20):2501-55
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541-619
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45(2):246-51
   PubMed Web of Science ®Google Scholar
• Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007;49(22):2145-50
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999;42(2):213-20
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JTIII, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008;121(4):527-34
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv 2014;7(4):435-42
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Tello-Montoliu A, et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. J Thromb Thrombolysis 2013;35(2):155-64
   PubMed Web of Science ®Google Scholar
• Ringwala SM, Dibattiste PM, Schneider DJ. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis 2012;34(3):291-6
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012;34(1):44-55
   PubMed Web of Science ®Google Scholar
• Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010;50(1):27-35
   PubMed Web of Science ®Google Scholar
• Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002;24(5):752-65
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007;154(4):702-9
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part,phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151(3):689.e1-689.e10
   Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361(24):2330-41
   PubMed Web of Science ®Google Scholar
• Leonardi S, Truffa AA, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart 2013;99(17):1282-7
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361(24):2318-29
   PubMed Web of Science ®Google Scholar
• Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012;163(5):768-776.e2
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368(14):1303-13
   PubMed Web of Science ®Google Scholar
• Généreux P, Stone GW, Harrington RA, et al. CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014;63(7):619-29
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Pokov AN, Fortmann SD, DiNicolantonio JJ. Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. Thromb Haemost 2014;111(1):3-7
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307(3):265-74
   PubMed Web of Science ®Google Scholar
• Firstenberg MS, Dyke CM, Angiolillo DJ, et al. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. Heart Surg Forum 2013;16(2):E60-9
   Google Scholar
• Voeltz MD, Manoukian SV. Cangrelor in patients undergoing cardiac surgery: the BRIDGE study. Expert Rev Cardiovasc Ther 2013;11(7):811-16
   PubMedGoogle Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85(3):401-7
   PubMed Web of Science ®Google Scholar
• Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial – phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11(1):1-11
   PubMed Web of Science ®Google Scholar
• Green CL, Whellan DJ, Lambe L, et al. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. J Cardiovasc Pharmacol 2013;62(5):466-78
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Sibbing D, DiNicolantonio JJ. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology 2014;127(1):20-4
   PubMed Web of Science ®Google Scholar
• Pandit A, Aryal MR, Aryal Pandit A, et al. Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis. EuroIntervention 2014;9(11):1350-8
   PubMedGoogle Scholar
• Sardar P, Nairooz R, Chatterjee S, et al. Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials. J Thromb Thrombolysis 2014;38(1):1-10
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382(9909):1981-92
   PubMed Web of Science ®Google Scholar
• Waite LH, Phan YL, Spinler SA. Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Pharmacotherapy 2014;34(10):1061-76
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355(21):2203-16
   PubMed Web of Science ®Google Scholar
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329(10):673-82
   PubMed Web of Science ®Google Scholar
• Marino M, Rizzotti D, Leonardi S. Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX). Curr Cardiol Rep 2014;16(6):493
   PubMedGoogle Scholar
• Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50(22):2173-95
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123(23):2736-47
   PubMed Web of Science ®Google Scholar